Pharmaceuticals China

China Cancer Vaccines Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

China Cancer Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $669.0 Mn Placeholder estimate
Estimate 2025 $754.7 Mn 8.7% of the global market
Projected 2034 $2.23 Bn 195.7% Adds $1.48 Bn over 9 forecast years
CAGR 2025–2034 12.8% Faster than 65% of 180 Pharmaceuticals markets here
Key players 5
  • China is 8.75% of the global market.
  • In APAC, the largest is China (this report) at $754.7 Mn.
  • Fastest growing: India at 14.4% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.48 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Cancer Vaccines Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $669.0 Mn — —
2025 (base) $754.7 Mn +$85.6 Mn —
2026 (forecast) $851.2 Mn +$96.6 Mn +12.8%
2027 (forecast) $960.2 Mn +$109.0 Mn +27.2%
2028 (forecast) $1.08 Bn +$122.9 Mn +43.5%
2029 (forecast) $1.22 Bn +$138.6 Mn +61.9%
2030 (forecast) $1.38 Bn +$156.4 Mn +82.6%
2031 (forecast) $1.55 Bn +$176.4 Mn +106%
2032 (forecast) $1.75 Bn +$199.0 Mn +132.4%
2033 (forecast) $1.98 Bn +$224.5 Mn +162.1%
2034 (forecast) $2.23 Bn +$253.2 Mn +195.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

China Cancer Vaccines Market Analysis at a glance
Market size, 2025$754.7 Mn placeholder estimate
Forecast, 2034$2.23 Bn placeholder estimate
Growth (CAGR), 2025–203412.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, indication and end user (see all)
Key playersModerna, Merck & Co., Inc., BioNTech, Dendreon Pharmaceuticals LLC, Gritstone bio (see all)
Regulator in ChinaNMPASource: National Medical Products Administration. Checked 14 Nov 2026.
Active clinical trials113 in ChinaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The China Cancer Vaccines Market Analysis Executive Summary

Cancer vaccines train the immune system to recognise and attack cancer, including personalised mRNA vaccines and preventive vaccines.

Key segments of the cancer Vaccines market include type (Personalized Neoantigen Vaccines, Preventive Vaccines and Dendritic Cell Vaccines) and indication (Melanoma, Lung Cancer and Prostate Cancer).

Bar chart: China Cancer Vaccines market size, 2024–2034, placeholder estimates. $669.0 Mn in 2024, $754.7 Mn in 2025 and $2.23 Bn in 2034, 12.8% CAGR.
China Cancer Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

China Cancer Vaccines Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the cancer Vaccines market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the cancer Vaccines market, especially in low- and middle-income countries.

Competitive Landscape for Cancer Vaccines Market in China

The cancer Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Cancer Vaccines Market in China

Cancer Vaccines in China: rules, payment and research

Drugs need approval from the National Medical Products Administration (NMPA) before sale.⁠[1] Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List.⁠[2] ClinicalTrials.gov lists 113 studies on Cancer Vaccines that are recruiting, active or about to start in China.⁠[3]

[1] National Medical Products Administration. Checked 14 Nov 2026.

[2] National Healthcare Security Administration. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for cancer Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Cancer Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Cancer Vaccines in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Cancer Vaccines market in China?
Placeholder estimate: about $754.7 Mn in 2025, rising to about $2.23 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Cancer Vaccines market in China growing?
Placeholder estimate: about 12.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Cancer Vaccines market report cover?
The report splits the market by type (Personalized Neoantigen Vaccines, Preventive Vaccines, Dendritic Cell Vaccines, Viral Vector Vaccines), indication (Melanoma, Lung Cancer, Prostate Cancer, Cervical Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Cancer Vaccines market?
Key players include Moderna, Merck & Co., Inc., BioNTech, Dendreon Pharmaceuticals LLC and Gritstone bio.
What is driving the Cancer Vaccines market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the cancer Vaccines market. Faster approvals and new combinations are improving survival.
Who regulates Cancer Vaccines in China?
Drugs need approval from the National Medical Products Administration (NMPA) before sale. Source: National Medical Products Administration. Checked 14 Nov 2026.
How is healthcare paid for in China?
Basic medical insurance covers most people; the National Healthcare Security Administration (NHSA) runs it and sets the National Reimbursement Drug List. Source: National Healthcare Security Administration. Checked 14 Nov 2026.
How many clinical trials on Cancer Vaccines are running in China?
113 studies are recruiting, active or about to start in China, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.
How much research is published on Cancer Vaccines?
PubMed lists 2,635 papers on Cancer Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on oncology and vaccines

See the topic